cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Verastem Inc
16 own
43 watching
Current Price
$0.71
$0.01
(0.74%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
148.15M
52-Week High
52-Week High
2.13
52-Week Low
52-Week Low
0.2895
Average Volume
Average Volume
0.69M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization148.15M
icon52-Week High2.13
icon52-Week Low0.2895
iconAverage Volume0.69M
iconDividend Yield--
iconP/E Ratio--
What does the Verastem Inc do?
Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing drugs targeting cancer stem cells (CSCs). Its programs target the focal adhesion kinase (FAK) and the PI3K/mTOR signaling pathways. The company's product candidate FAK inhibitor, VS-6063, is in Phase 1 study in combination with PD-1 inhibitor pembrolizumab and gemcitabine for pancreatic cancer; a Phase Ib clinical trial in combination with paclitaxel for patients with ovarian cancer; a Phase II study in patients with non-small cell lung cancer; a Phase II trial preceding surgery in mesothelioma; and a Phase 1/1b clinical trail in combination with avelumab in patients with ovarian cancer, as well as a combination trial of VS-6063 and VS-5584 in patients with relapsed mesothelioma. It is also developing FAK inhibitor, VS-4718 that is in Phase 1, single-agent, dose escalation trial in patients with advanced cancers; and a Phase 1, dose-escalation clinical trial in combination with gemcitabine and nab-paclitaxel in patients with advanced solid tumors, as well as a Phase 1, dose-escalation clinical trial of PI3K/mTORC1/2 inhibitor, VS-5584, in patients with advanced non-hematologic malignancies or lymphoma. The company has license agreement with Whitehead Institute for Biomedical Research; The Scripps Research Institute; and Pfizer, Inc. Verastem, Inc. was founded in 2010 and is based in Needham, Massachusetts.
Read More
How much money does Verastem Inc make?
News & Events about Verastem Inc.
Ticker Report
2 months ago
StockNews.com started coverage on shares of Verastem (NASDAQ:VSTM Get Rating) in a research note published on Monday morning. The brokerage issued a hold rating on the biopharmaceutical companys stock. A number of other equities research analysts have also recently weighed in on the ...
Zolmax
2 months ago
StockNews.com started coverage on shares of Verastem (NASDAQ:VSTM Get Rating) in a research note published on Monday morning. The brokerage issued a hold rating on the biopharmaceutical companys stock. A number of other equities research analysts have also recently weighed in on the stock. HC ...
Ticker Report
5 months ago
Principal Financial Group Inc. lowered its stake in shares of Verastem, Inc. (NASDAQ:VSTM Get Rating) by 27.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 200,197 shares of the biopharmaceutical companys stock after selling 74,...
Zolmax
6 months ago
Verastem, Inc. (NASDAQ:VSTM Get Rating) saw a large decline in short interest in the month of June. As of June 30th, there was short interest totalling 4,850,000 shares, a decline of 40.6% from the June 15th total of 8,160,000 shares. Based on an average daily volume of 2,460,000 shares, the days-to...
Frequently Asked Questions
Frequently Asked Questions
What is Verastem Inc share price today?
plus_minus_icon
Can Indians buy Verastem Inc shares?
plus_minus_icon
How can I buy Verastem Inc shares from India?
plus_minus_icon
Can Fractional shares of Verastem Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Verastem Inc stocks?
plus_minus_icon
What is today’s traded volume of Verastem Inc?
plus_minus_icon
What is today’s market capitalisation of Verastem Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Verastem Inc?
plus_minus_icon
What percentage is Verastem Inc down from its 52-Week High?
plus_minus_icon
What percentage is Verastem Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0.71
$0.01
(0.74%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc.
$68.70
$-5.59 (-7.52 %)
PROQR THERAPEUTICS NV
PROQR THERAPEUTICS NV
$3.15
$0.30 (10.53 %)
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
$2.90
$-0.05 (-1.69 %)
MARINUS PHARMACEUTICALS INC
MARINUS PHARMACEUTICALS INC
$6.53
$-0.12 (-1.88 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc.
$68.70
$-5.59 (-7.52 %)
PROQR THERAPEUTICS NV
PROQR THERAPEUTICS NV
$3.15
$0.30 (10.53 %)
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
$2.90
$-0.05 (-1.69 %)
MARINUS PHARMACEUTICALS INC
MARINUS PHARMACEUTICALS INC
$6.53
$-0.12 (-1.88 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00